Proteins & Peptides

Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.429, also known as variant Epsilon, originally identified in California (USA), and contains mutations W152C, L452R, D614G in addition to 682RRAR685>A and K986P, V987P. The construct also contains a C-terminal His-tag (6His). The recombinant protein was affinity purified.

Please note this product may be subject to fees, we invite you to contact your local office. This antibody is a humanized monoclonal antibody which recognizes SARS-CoV-2 spike RBD and the full-length spike proteins in the native trimeric conformation. This antibody is derived from rabbit monoclonal C-A11 neutralizing antibody (BPS Bioscience, #101024). It cross-reacts with the wildtype as well as the B.1.617.2 (Delta Variant), B.1.617.2.1 (Delta PLUS Variant), B.1.1.7 (Alpha Variant) RBDs and spike protein trimers [See Table of variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Sike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits (available for purchase).

Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV2 Variant P.1, also known as variant Gamma, originally discovered in Brazil and contains all P.1 mutations in addition to 682RRAR685>A, as listed below. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified.